[go: up one dir, main page]

AU2002228805A1 - Antisense modulation of damage-specific dna binding protein 2, p48 expression - Google Patents

Antisense modulation of damage-specific dna binding protein 2, p48 expression

Info

Publication number
AU2002228805A1
AU2002228805A1 AU2002228805A AU2880502A AU2002228805A1 AU 2002228805 A1 AU2002228805 A1 AU 2002228805A1 AU 2002228805 A AU2002228805 A AU 2002228805A AU 2880502 A AU2880502 A AU 2880502A AU 2002228805 A1 AU2002228805 A1 AU 2002228805A1
Authority
AU
Australia
Prior art keywords
expression
damage
binding protein
dna binding
specific dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002228805A
Inventor
Ian Popoff
Jacqueline R Wyatt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ionis Pharmaceuticals Inc
Original Assignee
Isis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc
Publication of AU2002228805A1 publication Critical patent/AU2002228805A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2002228805A 2000-12-06 2001-12-04 Antisense modulation of damage-specific dna binding protein 2, p48 expression Abandoned AU2002228805A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/732,199 US6379960B1 (en) 2000-12-06 2000-12-06 Antisense modulation of damage-specific DNA binding protein 2, p48 expression
US09732199 2000-12-06
PCT/US2001/046480 WO2002046473A1 (en) 2000-12-06 2001-12-04 Antisense modulation of damage-specific dna binding protein 2, p48 expression

Publications (1)

Publication Number Publication Date
AU2002228805A1 true AU2002228805A1 (en) 2002-06-18

Family

ID=24942580

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002228805A Abandoned AU2002228805A1 (en) 2000-12-06 2001-12-04 Antisense modulation of damage-specific dna binding protein 2, p48 expression

Country Status (3)

Country Link
US (1) US6379960B1 (en)
AU (1) AU2002228805A1 (en)
WO (1) WO2002046473A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105037A1 (en) * 2001-10-06 2003-06-05 Isis Pharmaceuticals Inc. Antisense modulation of inhibitor-kappa B kinase-gamma expression
US7658938B2 (en) * 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
EP1390383B1 (en) * 2001-05-11 2012-02-29 Isis Pharmaceuticals, Inc. Antisense permeation enhancers
MX2008012678A (en) * 2006-04-07 2008-12-17 Merrion Res Iii Ltd Solid oral dosage form containing an enhancer.
WO2007146234A2 (en) * 2006-06-09 2007-12-21 Merrion Research Ii Limited Solid oral dosage form containing an enhancer
US9808557B2 (en) 2007-08-10 2017-11-07 Trustees Of Tufts College Tubular silk compositions and methods of use thereof
CA2723541A1 (en) * 2008-05-07 2009-11-12 Merrion Research Iii Limited Compositions of peptides and processes of preparation thereof
TWI480286B (en) * 2009-02-25 2015-04-11 Merrion Res Iii Ltd Composition and drug delivery of bisphosphonates
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
WO2011120033A1 (en) * 2010-03-26 2011-09-29 Merrion Research Iii Limited Pharmaceutical compositions of selective factor xa inhibitors for oral administration
CA2819234A1 (en) 2011-01-07 2012-07-12 Merrion Research Iii Limited Pharmaceutical compositions of iron for oral administration
WO2016120378A1 (en) 2015-01-29 2016-08-04 Novo Nordisk A/S Tablets comprising glp-1 agonist and enteric coating

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5951455A (en) * 1998-12-04 1999-09-14 Isis Pharmaceuticals, Inc. Antisense modulation of G-alpha-11 expression

Also Published As

Publication number Publication date
WO2002046473A1 (en) 2002-06-13
US6379960B1 (en) 2002-04-30

Similar Documents

Publication Publication Date Title
AU6508499A (en) Antisense modulation of microtubule-associated protein 4 expression
AU4193700A (en) Antisense oligonucleotide compositions and methods for the modulation of jnk proteins
AU7097400A (en) Platelet membrane glycoprotein vi (gpvi) dna and protein sequences, and uses thereof
AU4065000A (en) Antisense modulation of p38 mitogen activated protein kinase expression
AU4498500A (en) Phytyl/prenyltransferase nucleic acids, polypeptides and uses thereof
AU1221201A (en) Antisense modulation of y-box binding protein 1 expression
AU2002228805A1 (en) Antisense modulation of damage-specific dna binding protein 2, p48 expression
AU2002218269A1 (en) Proteins and dna sequences underlying these proteins used for treating inflammations
AU2001257220A1 (en) Antisense modulation of inhibitor of dna binding-1 expression
AU2001287136A1 (en) Antisense modulation of glioma-associated oncogene-1 expression
AU2001274566A1 (en) Novel protein and dna thereof
AU2001296413A1 (en) Oligonucleotide modulation of her-1 expression
AU2001292790A1 (en) Antisense modulation of syntaxin 4 interacting protein expression
AU2001268322A1 (en) Antisense modulation of c/ebp alpha expression
AU3556800A (en) Expression of dna or proteins in (c. elegans)
AU4684099A (en) Oligonucleotides for enhanced modulation of protein kinase expression
AU2001290872A1 (en) Isolated human kinase proteins, nucleic acid molecules and uses thereof
AU2002241586A1 (en) Antisense modulation of damage-specific dna binding protein 1, p127 expression
AU8229901A (en) Genes and proteins, and their uses
AU2002245190A1 (en) Antisense modulation of integrin beta 4 binding protein expression
AU2001271276A1 (en) Isolated human aminotransferase proteins, nucleic acid molecules encoding human aminotransferase proteins, and uses thereof
AU1320600A (en) Human rna binding proteins
AU2225401A (en) Novel protein and dna thereof
AU1690200A (en) Novel protein and dna thereof
AU2001259240A1 (en) Novel stmst protein and nucleic acid mocecules and uses therefor